Hetero Labs Limited Lenalidomide Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Lenalidomide Export Records India — #6 Exporter, 23 Shipments, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Lenalidomide

India Pharmaceutical Trade Intelligence

$883.1M237 Suppliers122 CountriesHS 30049049

ExportsIndia → UNITED STATES96.7%India → JAPAN0.6%

ImportsUNITED STATES → India$1.6M SWITZERLAND → India$1.3M

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: SUN PHARMACEUTICAL

Hetero Labs Limited — Lenalidomide Exporter #6 | $1.1M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Lenalidomide Exporter Profile

Indian Pharmaceutical Exporter · #6 for Lenalidomide · $1.1M export value · DGFT Verified

Hetero Labs Limited is the #6 Indian exporter of Lenalidomide with $1.1M in export value and 23 verified shipments. Hetero Labs Limited holds a 0.8% market share in Lenalidomide exports across 8 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Lenalidomide Export Profile: Buyers & Destinations

Hetero Labs Limited Lenalidomide export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Lenalidomide?

Country	Value	Shipments	Share
JAPAN	$98.9K	2	73.8%
DOMINICAN REPUBLIC	$15.0K	1	11.2%
HONDURAS	$9.5K	2	7.1%
EL SALVADOR	$5.3K	1	3.9%
NETHERLANDS

Who Are the Top Buyers of Lenalidomide from Hetero Labs Limited?

Buyer	Country	Value	Orders
XXC (XXNG XXNG)XXO XXD	JAPAN	$98.9K	2
XXVENXXHARXX DRXXRL	DOMINICAN REPUBLIC	$15.0K	1
XXVENXXHARXX HOXXURAXXS AX	HONDURAS	$9.5K	2
XXVENXXHARXX ELXXALVXXOR XXA XX C XX	EL SALVADOR	$5.3K	1
XXAROXXPHAXXA BXX	NETHERLANDS	$5.1K	1
CAMBER FARMACEUTICA LTDA.	BRAZIL	$15	4
M S MAKIZ PHARMA LIMITED	RUSSIA	$4	1
M/S MAKIZ PHARMA LIMITED	RUSSIA	$0	3
TO THE ORDER OF	BELARUS	$0	6
TO M S MAKIZ PHARMA LIMITED	RUSSIA	$0	1

Hetero Labs Limited supplies Lenalidomide to 11 buyers globally. The largest buyer is XXC (XXNG XXNG)XXO XXD (JAPAN), followed by XXVENXXHARXX DRXXRL (DOMINICAN REPUBLIC) and XXVENXXHARXX HOXXURAXXS AX (HONDURAS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Lenalidomide Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
LENALIDOMIDE 5MG CAPSULES (20X10'S)	$50.0K	1
LENALIDOMIDE 2.5MG CAPSULES (20X10'S)	$48.9K	1
LENALIDOMIDE 25MG CAPSULES	$24.6K	3
LENALIDOMIDE 10MG CAPSULES (1X28'S)	$5.3K	1
LENALIDOMIDE 25MG CAPSULES (3X7'S)	$5.1K	1
LENALIDOMIDE CAPSULES 5MG	$4	1
LENALIDOMIDE CAPSULES 25MG	$4	1
LENALIDOMIDE FORM H1 WS QTY 0 800GRAMS	$4	1
LENALIDOMIDE CAPSULES 10MG	$3	1
LENALIDOMIDE CAPSULES 15MG	$3	1

Hetero Labs Limited exports 21 distinct Lenalidomide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LENALIDOMIDE 5MG CAPSULES (20X10'S) with 1 shipments worth $50.0K.

How Does Hetero Labs Limited Compare to Nearest Lenalidomide Exporters?

Exporters ranked immediately above and below #6 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$7.2M	144	6	$50.0K
4	CIPLA LIMITED	$2.1M	42	6	$50.0K
6	HETERO LABS LIMITED ★	$1.1M	23	8	$50.0K
7	NATCO PHARMA LIMITED	$1.1M	31	6	$35.6K
3	DR REDDYS LABORATORIES LIMITED	$200.0K	4	3	$50.0K

Hetero Labs Limited ranks #6 among 237 Indian Lenalidomide exporters. Average shipment value of $50.0K compared to the market average of $128.1K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and CIPLA LIMITED.

Which Indian Ports Ship Lenalidomide Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	740	27.2%
SAHAR AIR	688	25.3%
DELHI AIR CARGO ACC (INDEL4)	187	6.9%
Bombay Air	180	6.6%
DELHI AIR	140	5.1%
Bombay Air Cargo	88	3.2%
HYDERABAD ACC (INHYD4)	78	2.9%
HYDERABAD AIR	68	2.5%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Lenalidomide Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Lenalidomide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 23 individual customs records matching Hetero Labs Limited exporting Lenalidomide, covering 21 formulations to 8 countries via 11 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 122+ countries, 557+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Lenalidomide

Lenalidomide

Hetero Labs Limited — Lenalidomide Exporter Profile

Hetero Labs Limited — Lenalidomide Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Lenalidomide?

Who Are the Top Buyers of Lenalidomide from Hetero Labs Limited?

What Is India's Total Lenalidomide Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Lenalidomide Exports?

How Does Hetero Labs Limited Compare to Other Indian Lenalidomide Exporters?

What Lenalidomide Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Lenalidomide to Key Markets

Japan — PMDA

How Does Hetero Labs Limited Compare to Nearest Lenalidomide Exporters?

Which Indian Ports Ship Lenalidomide Exports?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Lenalidomide Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Lenalidomide Export Data from Hetero Labs Limited

Lenalidomide Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source